The FINANCIAL — Sanofi announced today that the U.S. District Court for the District of New Jersey has ruled against Sun Pharmaceuticals LTD. (Sun) in favor of Sanofi U.S. with respect to a contractual dispute arising from the resolution of the Eloxatin (oxaliplatin) patent litigation.
Sun had appealed the District Court’s April 2010 ruling requiring Sun to cease selling its at-risk generic oxaliplatin products as of June 30, 2010. In December 2010 the U.S. Court of Appeals for the Federal Circuit vacated the District Court’s ruling and remanded the case to the District Court of New Jersey for further consideration.
The District Court’s latest ruling maintains Eloxatin’s US market exclusivity through August 9, 2012.
Sanofi remains committed to Eloxatin as an important therapeutic option for healthcare professionals
treating patients with colorectal cancer
Discussion about this post